Humacyte (NASDAQ:HUMA) Given New $3.50 Price Target at TD Cowen

Humacyte (NASDAQ:HUMA) had its price objective lowered by TD Cowen from $5.00 to $3.50 in a research report report published on Tuesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other research analysts have also issued reports on HUMA. Wall Street Zen raised shares of Humacyte from a “sell” rating to a “hold” rating in a research note on Saturday. HC Wainwright cut their target price on shares of Humacyte from $4.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday. Benchmark cut their target price on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Wednesday, May 14th. Finally, D. Boral Capital reaffirmed a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a research note on Monday. Two research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Humacyte has a consensus rating of “Moderate Buy” and a consensus price target of $10.64.

Humacyte Stock Up 2.9%

Shares of NASDAQ HUMA opened at $1.80 on Tuesday. The firm has a market cap of $278.44 million, a PE ratio of -3.99 and a beta of 1.90. Humacyte has a 12-month low of $1.15 and a 12-month high of $7.48. The company’s fifty day simple moving average is $2.36 and its 200 day simple moving average is $2.51. The company has a quick ratio of 3.28, a current ratio of 3.68 and a debt-to-equity ratio of 0.36.

Humacyte (NASDAQ:HUMA) last issued its earnings results on Monday, August 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.09). The company had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.94 million. As a group, sell-side analysts forecast that Humacyte will post -1.27 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in HUMA. Vanguard Group Inc. lifted its stake in shares of Humacyte by 10.8% in the fourth quarter. Vanguard Group Inc. now owns 5,602,684 shares of the company’s stock valued at $28,294,000 after buying an additional 543,995 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Humacyte by 4.7% during the fourth quarter. Geode Capital Management LLC now owns 2,135,133 shares of the company’s stock valued at $10,785,000 after purchasing an additional 94,915 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Humacyte by 40.9% during the fourth quarter. Wells Fargo & Company MN now owns 50,454 shares of the company’s stock valued at $255,000 after purchasing an additional 14,649 shares in the last quarter. Legal & General Group Plc lifted its position in shares of Humacyte by 19.5% during the fourth quarter. Legal & General Group Plc now owns 81,405 shares of the company’s stock valued at $411,000 after purchasing an additional 13,293 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in shares of Humacyte during the fourth quarter valued at about $377,000. 44.71% of the stock is owned by institutional investors.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.